Stay updated on FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial

Sign up to get notified when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A site-wide NIH notice about terminology changes during a transition appears above the 403 error message.
    Difference
    1%
    Check dated 2026-10-25T06:47:24.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov error page’s footer revision changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T06:34:06.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-11T08:19:12.000Z thumbnail image
  4. Check
    36 days ago
    Change Detected
    Summary
    A 403 Forbidden page is displayed for the study record, replacing the normal content and navigation; the study details are now inaccessible due to access restrictions.
    Difference
    20%
    Check dated 2026-09-20T03:18:34.000Z thumbnail image
  5. Check
    57 days ago
    Change Detected
    Summary
    Revision updated from v3.6.5 to v3.6.6, indicating a minor metadata update to the study record. It does not imply changes to the study content or displayed information.
    Difference
    0.1%
    Check dated 2026-08-30T00:32:01.000Z thumbnail image
  6. Check
    79 days ago
    Change Detected
    Summary
    Page revision updated from v3.6.4 to v3.6.5, indicating a maintenance update to the ClinicalTrials.gov page. No substantive study content appears to be altered.
    Difference
    0.0%
    Check dated 2026-08-08T23:00:26.000Z thumbnail image

Stay in the know with updates to FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.